Share on StockTwits

ACADIA Pharmaceuticals (NASDAQ:ACAD) CEO Uli Hacksell sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $17.75, for a total transaction of $443,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of ACADIA Pharmaceuticals from $26.00 to $38.00 in a research note on Tuesday, March 4th. Separately, analysts at Zacks downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 27th. Finally, analysts at Zacks reiterated an “outperform” rating on shares of ACADIA Pharmaceuticals in a research note on Wednesday, January 22nd. They now have a $26.00 price target on the stock. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $26.33.

Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) traded up 0.83% on Thursday, hitting $19.44. The stock had a trading volume of 2,154,396 shares. ACADIA Pharmaceuticals has a 52-week low of $11.26 and a 52-week high of $32.00. The stock has a 50-day moving average of $24.81 and a 200-day moving average of $24.11. The company’s market cap is $1.776 billion.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.13) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.14) by $0.01. On average, analysts predict that ACADIA Pharmaceuticals will post $-0.55 earnings per share for the current fiscal year.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.